For example, obese diabetics are a special case and should not be given the full mortality and morbidity benefit for the weight-loss indication in addition to the diabetes indication
Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia
Nausea and Vomiting Nausea from GLP 1 drugs is the most frequently reported symptom
The mView product specification includes all detectable compounds of known identity (named biochemicals)